Loading
Zanzalintinib is an experimental small-molecule drug from Exelixis in phase 3 trials for neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma, aimed at VEGF / VEGFR and MET.
Zanzalintinib (XL092) is a small-molecule drug developed by Exelixis and Merck Sharp & Dohme. Its targets are VEGF / VEGFR and MET (the sponsor names MET/VEGFR/AXL/MER). The sponsor states: Exelixis describes zanzalintinib as a next-generation tyrosine kinase inhibitor (TKI) targeting MET, VEGFR, AXL and MER receptors. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumours), NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma) and NCT07227402 (A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)), in neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma. The largest, NCT07227402, plans to enrol 904 participants with primary completion expected 2032-02-27. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Exelixis describes zanzalintinib as a next-generation tyrosine kinase inhibitor (TKI) targeting MET, VEGFR, AXL and MER receptors. Connects to VEGF / VEGFR and MET.
1.Zanzalintinib slips into a pocket on VEGF / VEGFR.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Zanzalintinib" OR ABSTRACT:"Zanzalintinib" OR TITLE:"XL092" OR ABSTRACT:"XL092") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zanzalintinib, not a curated reading list.
Shares Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
Shares Merck & Co. (MSD), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
Shares Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
Shares Neuroendocrine tumours, Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.